Precision Logistics to Speed Up Clinical Trials
Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Dr David Hayes explains why clinical research should be embedded early in cardiac device development and not treated as a late-stage compliance step.
AI is tackling the pharmaceutical supply chain's most persistent problems, from demand forecasting to counterfeit detection. See the top 7 ways AI is improving supply chain resiliency.
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
The USP's 2025 Vulnerable Medicines List flags 100 drugs at high risk. Here is what to do to build pharma supply chain resilience.